Table 3. Association between resistance profile and clinical outcomes (n = 560).

Resistance categories and clinical outcomes are not mutually exclusive. A single isolate or patient may fall into multiple categories or outcomes; therefore, totals may exceed n = 560

MDR: multidrug-resistant; ESBL: extended-spectrum beta-lactamase; MRSA: methicillin-resistant Staphylococcus aureus

Resistance profile	Treatment failure, n (%)	Hospital stay >5 days, n (%)	Antibiotic escalation, n (%)	Inhospital mortality, n (%)
MDR pathogens (n = 188)	72 (38.30)	101 (53.72)	129 (68.62)	21 (11.17)
Non-MDR pathogens (n = 372)	47 (12.63)	86 (23.12)	68 (18.28)	9 (2.42)
ESBL producers (n = 142)	58 (40.85)	85 (59.86)	102 (71.83)	17 (11.97)
Carbapenem-resistant (n = 32)	19 (59.38)	26 (81.25)	28 (87.50)	9 (28.13)
MRSA (oxacillin-resistant) (n = 67)	24 (35.82)	36 (53.73)	42 (62.69)	6 (8.96)